Mortality is influenced by locality in a major HIV/AIDS epidemic

HIV Medicine

Volumn 10, Issue 5, 2009, Pages 274-281

  Druyts, E F ^a   Rachlis, B S ^a,b   Lima, V D ^a,c   Harvard, S S ^a   Zhang, W ^a   Brandson, E K ^a   Strathdee, S A ^a,d   Montaner, J S G ^a,c   Hogg, R S ^a,e  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Antiretroviral therapy; HAART; HIV AIDS; Mortality; Neighbourhood

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; CLINICAL COMPETENCE; CONTROLLED STUDY; EPIDEMIC; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MORTALITY; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SOCIOECONOMICS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRITISH COLUMBIA; CLINICAL COMPETENCE; DISEASE OUTBREAKS; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; SUBSTANCE ABUSE, INTRAVENOUS; URBAN POPULATION;

EID: 65449167556     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00684.x     Document Type: Article

References (36)

1. Hogg RS, Heath KV, Strathdee SA et al. HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials. AIDS 1996; 10: 889-894.
2. Schanzer DL. Trends in HIV/AIDS mortality in Canada, 1987-1998. Can J Pub Health 2003; 94: 135-139.
3. Wood E, Low-Beer S, Bartholomew K et al. Modern antiretroviral therapy improves life expectancyof gay and bisexual males in Vancouver's West End. Can J Pub Health 2000; 91: 125-128.
4. Joy R, Druyts EF, Brandson EK et al. Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting. J Acquir Immune Defic Syndr 2008; 47: 500-505.
5. Low-Beer S, Bartholomew K, Weber AE et al. A demographic and health profile of gay and bisexual men in a large Canadian urban setting. AIDS Care 2002; 14: 111-115.
6. Buxton J. 2003. Vancouver drug use epidemiology. Site report for the Canadian Community Epidemiology Network on Drug Use. Available at http://www.vancouver.ca/foupillars/pdf/report_vancouver_2005.pdf. Accessed on March 19, 2007.
7. Kuyper LM, Hogg RS, Montaner JS et al. The cost of inaction on HIV transmission among injection drug users and the potential for effective interventions. J Urban Health 2004; 81: 655-660.
8. Maas B, Fairburn N, Kerr T et al. Neighborhood and HIV infection among IDU: Place of residence independently predicts HIV infection among a cohort of injection drug users. Health Place 2007; 13: 432-439.
9. Gulick RM, Mellors JW, Havlir D et al. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection, 100-week follow-up. JAMA 1998; 280: 35-41.
10. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-733.
11. Montaner JS, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998; 279: 930-937.
12. Lima VD, Hogg RS, Harrigan PR et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685-692.
13. Montaner JS, Hogg RS, Wood E et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 364: 11-12.
14. Lima VD, Johnson K, Hogg RS et al. Expanded access to highly active antiretroviral therapy: A potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 2008; 198: 59-67.
15. Wood E, Montaner JS, Chan K et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS 2002; 16: 1-8.
16. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286: 2568-2577.
17. Hammer SM, Saag MS, Schecter M et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2006; 296: 827-843.
18. Wood E, Montaner JS, Yip B et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1-infected injection drug users. Can Med Assoc J 2003; 169: 656-661.
19. Wood E, Hogg RS, Yip B et al. Is there a baseline CD4 that precludes a survival response to modern antiretroviral therapy? AIDS 2003; 17: 711-720.
20. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary NC: SAS Institute Inc, 1995.
21. Lima VD, Kopec JA. Quantifying the effect of health status on health care utilization using a preference-based health measure. Soc Sci Med 2005; 60: 515-524.
22. British Columbia Centre for Excellence in HIV/AIDS. Drug Treatment Program Update. February 2008. Available at http://www.cfenet.ubc.ca/ webuploads/files/Feb08_DTP_update.pdf. Accessed on March 10, 2008.
23. Lochner KA, Kawachi I, Brennan RT et al. Social capital and neighborhood mortality rates in Chicago. Soc Sci Med 2003; 56: 1797-1805.
24. Macintyre S, Maciver S, Sooman A. Area, class and health: Should we be focusing on places or people? J Soc Pol 1993; 22: 213-234.
25. Heckman TG, Somlai AM, Peters J et al. Barriers to care among persons living with HIV/AIDS in urban and rural areas. AIDS Care 1998; 10: 365-375.
26. Rhodes T, Kimber J, Small W et al. Public injecting and the need for 'safer environment interventions'in the reduction of drug related harm. Addiction 2006; 101: 1384-1393.
27. Shapiro M, Morton S, McCaffrey DF et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA 1999; 281: 2305-2315.
28. Singer M. AIDS and the health crisis of the US urban poor: The perspective of critical medical anthropology. Soc Sci Med 1994; 39: 931-948.
29. Corneil T, Kuyper LM, Shoveller J et al. Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place 2006; 12: 79-85.
30. Normen L, Chan K, Braitstein P et al. Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada. J Nutr 2005; 135: 820-825.
31. Bangsberg DR, Hecht FM, Charlebois ED et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-366.
32. Shannon K, Kerr T, Lai C et al. Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Physicians AIDS Care (Chicago, IL) 2005; 4: 66-72.
33. Strathdee SA, Palepu A, Cornelisse PGA et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549.
34. Delgado J, Heath KV, Yip B et al. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. Antivir Ther 2003; 8: 471-478.
35. Demissie K, Hanley JA, Menzies D et al. Agreement in measuring socio-economic status: Area-based vs. individual measures. Chronic Dis Canada 2000; 21: 1-6.
36. Lima VD, Druyts EF, Fernandes KA et al. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. 17th International AIDS Conference. Mexico City, Mexico, August 2008 [Abstract MOPE0641].